Exelixis has regained from Bristol-Myers Squibb full development and commercialization rights to XL 184, its MET inhibitor currently in trials against 13 tumor types. The decision to return ‘184 to Exelixis arose from BMS’ prioritization of its internal oncology efforts. According to an Exelixis statement, “Given the recent progress of BMS’ wholly-owned oncology pipeline and positive data generated by XL184, Exelixis and BMS were not able to align on the scope, breadth and p...